Meeting Report
The Pharmacogenomics Journal (2006) 6, 82–88. doi:10.1038/sj.tpj.6500363; published online 10 January 2006
Retrospective validation of genomic biomarkers – what are the questions, challenges and strategies for developing useful relationships to clinical outcomes – workshop summary
S-J Wang1, N Cohen2, D A Katz3, G Ruano4, P M Shaw5 and B Spear3
- 1Office of Biostatistics, Office of Pharmacoepidemiology and Statistical Science, Center for Drug Evaluation and Research, US FDA, Silver Spring, MD, USA
- 2Johnson and Johnson Pharmaceutical R&D, Raritan, NJ, USA
- 3Abbott Laboratories, Abbott Park, IL, USA
- 4Genomas Inc., Hartford, CT, USA
- 5Merck & Corporation, Bluebell, PA, USA
Correspondence: Dr S-J Wang, Office of Biostatistics, OPaSS, CDER, Food & Drug Administration, HFD-700, WO 22, Room 6216, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA. Tel: +1 301 827 3089; Fax: +1 301 443 9279; E-mail: wangs@cder.fda.gov
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Clinical Pharmacology & Therapeutics News and Views
